Skip to main content
INOVIQ LTD logo

INOVIQ LTD — Investor Relations & Filings

Ticker · IIQ ISIN · AU0000196149 ASX Professional, scientific and technical activities
Open in API
Filings indexed 858 across all filing types
Latest filing 2018-08-20 Director's Dealing
Country AU Australia
Listing ASX IIQ

About INOVIQ LTD

https://www.inoviq.com

INOVIQ LTD specializes in the development and commercialization of next-generation exosome and precision diagnostics. The company focuses on innovative solutions for the early detection and monitoring of cancer and other diseases. Its proprietary technology portfolio includes EXO-NET, a high-throughput exosome capture tool designed for research and clinical applications, and the SubB2M platform, which utilizes an engineered protein to detect the pan-cancer biomarker Neu5Gc. The company also provides the hTERT test for bladder cancer monitoring. These technologies facilitate non-invasive liquid biopsy tests aimed at improving patient outcomes through high sensitivity and specificity. The core business activities encompass the creation of diagnostic tools and research reagents for the global healthcare and life sciences sectors, emphasizing precision medicine and early intervention.

Recent filings

Filing Released Lang Actions
Final Director's Interest Notice 2 pages 143.2KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Z Final Director’s Interest Notice' and references ASX listing rule 3.19A.3 and section 205G of the Corporations Act. It details the director's relevant interests in securities, including number and class of shares held, and notes the director ceased to be a director on a specific date. The content is focused on reporting personal share transactions or holdings by a company director. The document length is 2336 characters, which is relatively short and consistent with a director's dealing notice. There is no financial performance data, earnings information, or management discussion. Therefore, this document fits the category of Director's Dealing (DIRS).
2018-08-20 English
Death of Non-Executive Director 1 page 85.3KB
Board/Management Information Classification · 100% confidence The document is a short announcement regarding the death of a Non-Executive Director of the company. It does not contain financial data, regulatory filings, or any report content. It is an announcement related to the board of directors, specifically about a change due to the death of a board member. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused solely on this event, confirming it is not a report or other filing type.
2018-08-12 English
Quarterly Activities Report and Appendix 4C 7 pages 727.8KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'QUARTERLY BUSINESS UPDATE' and includes detailed financial data such as cash flows from operating, investing, and financing activities, cash balances, and estimated cash outflows for the next quarter. It also references the Appendix 4C quarterly report, which is a regulatory filing for entities subject to Listing Rule 4.7B, commonly used in Australian markets for quarterly reporting. The document contains substantive financial data and analysis for the quarter ended 30 June 2018, including operational updates and R&D progress. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements and substantive financial data. The document is not merely an announcement or a certification, but a full quarterly report with financial statements and business updates. Q4 2018
2018-07-31 English
US Patent Issued Protecting BARD1 Ovarian Test 2 pages 148.2KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing the issuance of a US patent for a cancer diagnostic test developed by BARD1 Life Sciences Limited. It discusses the patent details, the technology, and the company's business focus. There is no financial data, no regulatory filing, no management or board changes, no earnings or annual report content, and no shareholder voting or capital structure information. The document is an announcement of a patent grant, which is a regulatory or corporate announcement but does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is not a report publication announcement since it does not mention a report being published or attached. The best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2018-07-11 English
Appendix 3B Release of Securities from Escrow 12 pages 153.3KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including the number and class of securities issued, issue dates, shareholder approvals, and compliance with ASX listing rules. It includes calculations related to placement capacity under ASX rules 7.1 and 7.1A, which pertain to the company's ability to issue new shares without shareholder approval. The document is a formal announcement to the Australian Securities Exchange (ASX) regarding the release of shares from escrow and the application for quotation of additional securities. It is not a full financial report, earnings release, or management discussion, but rather a regulatory announcement about capital changes. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length (15,000 characters) and content confirm it is the announcement itself, not a brief notice or a report publication announcement.
2018-06-20 English
Improved Performance of BARD1 Ovarian Test 3 pages 132.7KB
Regulatory Filings Classification · 95% confidence The document is an announcement from BARD1 Life Sciences Limited about improved performance results of their BARD1-Ovarian test, including detailed study results, sensitivity, specificity, and potential clinical applications. It is presented as a press release with no comprehensive financial data, regulatory form references, or detailed financial statements. The content focuses on scientific and clinical study results rather than financial reporting or regulatory filings. The document length is over 10,000 characters, indicating it is not a brief announcement of a report publication. It is not a transcript, management change, or legal proceeding. The nature of the document is a corporate announcement of scientific study results and product development progress, which fits best under Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2018-06-18 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.